AIDSInfo logo
Home > Clinical Guidelines > Adult and Adolescent Guidelines

Adult and Adolescent Guidelines

Related Content
Order PublicationSupplementsSlide SetsManualsFact Sheets
DrugsHow to CiteClinical Trials 
DrugsBack
Adapted from Adult Treatment Guidelines Table 6: Antiretroviral Therapy for Treatment-Naive Patients (Updated November 3, 2008)

Patients naive to antiretroviral therapy should be started on a combination regimen that consists of either: 1 NNRTI + 2 NRTIs or 1 PI (preferably boosted with ritonavir) + 2 NRTIs 
  NNRTI Options Population in which to avoid or use with caution
Preferred  
  Efavirenz Do not use during 1st trimester of pregnancy or in those with high pregnancy potential  
      Use with caution in patients with unstable psychiatric disease  
         
  Alternative      
  Nevirapine   Do not use in patients with moderate to severe hepatic impairment (Child-Pugh score B or C)   
      Do not use in women with pre-ARV CD4 >250 or in men with pre-ARV CD4 >400  
      Use with caution in patients on tenofovir/emtricitabine (or lamivudine). Early virologic failure has been reported with this combination.   
PI Options Population in which to avoid or use with caution
  Preferred (alphabetical order)      
  Atazanavir + ritonavir (1x/day)   Do not use in patients who require high-dose (>20mg omeprazole equivalent/day) proton pump inhibitors (PPIs)  
  Darunavir +ritonavir (1x/day)      
  Fosamprenavir + ritonavir (2x/day)      
  Lopinavir/ritonavir (1x or 2x/day)   Do not use lopinavir/ritonavir in pregnant women   
  Alternative (alphabetical order)      
  Atazanavir (unboosted)(1x/day)   Do not use atazanavir in combination with tenofovir or didanosine/lamivudine  
  Fosamprenavir + ritonavir (1x/day) or fosamprenavir unboosted (2x/day)      
  Saquinavir + ritonavir (2x/day)      
         
  Dual-NRTI Options Population in which to avoid or use with caution
  Preferred      
  Emtricitabine/tenofovir   Do not use in combination with unboosted atazanavir  
      Use with caution:  
with nevirapine due to reports of early virologic failure
      in patients with underlying renal insufficiency  
  Alternative      
  Abacavir/lamivudine   Do not use in patients who test positive for HLAB*5701  
      Use with caution in the presence of the following:  
      HIV RNA >100,000 copies/mL - higher rate of virologic failure reported in ACTG 5205  
      High risk for cardiovascular disease  
  Didanosine + lamivudine (or emtricitabine)   Do not use in combination with unboosted atazanavir  
      Do not use in patients with a history of pancreatitis or peripheral neuropathy  
  Zidovudine/lamivudine   Do not use in combination with unboosted atazanavir  
      Do not use in patients with a history of pancreatitis or peripheral neuropathy  
      Use with caution in the presence of pretreatment anemia and/or neutropenia (may improve or worsen with zidovudine)  
         
         
CitationBack
How to Cite the Adult and Adolescent Guidelines:
Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3, 2008; pp 1-139. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed (insert date) [insert page number, table number, etc. if applicable]
Clinical TrialsBack
26 studies were listed in the last 30 days.            

RecruitingSafety and Efficacy of ADAPTAVIR's Ability to Eliminate Treatment-Resistant Infectious Virus in Peripheral Blood Mononuclear Cells (PBMCs)
Condition: HIV Infections
Not yet recruitingA Clinical Research Study for Assessing the Effectiveness of the New Integrase Inhibitor GSK1349572 in HIV-infected Persons With Prior Antiretroviral Treatment and Resistance to Raltegravir
Condition: HIV Infection
Not yet recruitingIntegration of Family Planning and HIV Services in Tanzania
Condition: HIV Infection
Not yet recruitingExamining Benefits of HAART Continuation in Postpartum Mothers
Condition: HIV Infections
RecruitingEffect of Antacids on the Pharmacokinetics of Raltegravir
Condition: HIV Infections
RecruitingFeasibility Study of a Multi-Component Intervention for Black Men Who Have Sex With Men
Condition: HIV Infections
Not yet recruitingEvaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients
Condition: HIV Infections
Not yet recruitingEvaluation of Maraviroc Intensification in HIV Infected Patients With Insufficient Immune Restoration
Condition: HIV Infection; HIV Infections
Not yet recruitingInterventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV
Condition: HIV Transmission; HIV Infections
Not yet recruitingComputerized HIV/Sexually Transmitted Disease (STD) Prevention Program
Condition: Acquired Immunodeficiency Syndrome; HIV Infections
RecruitingA Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects
Condition: HIV Infection; HIV-1 Infection
Not yet recruitingImmune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals
Condition: HIV Infections
RecruitingPharmacokinetic and Safety Study of Raltegravir and Atazanavir in a Once Daily Dose Regimen in HIV-1 Infected Patients
Condition: HIV Infection; HIV Infections
RecruitingRaltegravir Switch for Toxicity or Adverse Events
Condition: HIV/AIDS; Antiretroviral Therapy
Not yet recruitingExamining the Ability of Herpes Simplex Virus Type 2 (HSV2) Therapy to Reduce HIV Target Cell Numbers in the Cervix
Condition: Herpes Simplex Type Two Infection
RecruitingHuman Atherosclerotic Plaque Inflammation Imaged Using PDG-PET/CT
Condition: Insulin Resistance; Atherosclerosis; Cardiovascular Disease; HIV/AIDS
Not yet recruitingPatient Preference, Sleep Quality, and Anxiety/Depression: A Comparison of Raltegravir and Efavirenz
Condition: Sleep Disorders
Not yet recruitingGSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose Study
Condition: Healthy Volunteer
Not yet recruitingComparing Two Types of Swabs in Collecting Cell Samples for Anal Pap Tests and Human Papillomavirus Tests in Men Who Have Sex With Men
Condition: Anal Cancer; Precancerous/Nonmalignant Condition
RecruitingMolecular Biology of Anal Cancer in HIV-Positive Patients
Condition: Carcinoma
RecruitingTherapy Targeting Depression and HIV Treatment Adherence (The TRIAD Study)
Condition: HIV; Depression
Not yet recruitingSafety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.
Condition: HIV-1 Infection
Not yet recruitingAccuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts
Condition: HIV Infection; AIDS
Not yet recruitingReducing Sexual Risk Behaviors and Improving Health for People at a Sexually Transmitted Infection Clinic
Condition: HIV; Sexually Transmitted Diseases
RecruitingEquivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens
Condition: Pediatric HIV
RecruitingGenotypic Resistant HIV Strains in Taiwan
Condition: HIV-1
 
Important Notice:
This document has been submitted for publication to CDC's Morbidity and Mortality Weekly Report (MMWR) and should be considered a final draft. It is being posted on AIDSinfo to expedite dissemination of important clinical information. Upon acceptance and publication in MMWR, this draft will be removed and replaced by the published version. In the meantime, readers should be aware that the content of the draft might differ from the content of future published versions. Any corrections/questions concerning this document should be addressed to Ms. Jessica Carrington (e-mail: contactus@aidsinfo.nih.gov).
 
Close window